All > North Carolina > Synovial Sarcoma

CAB-AXL-ADC for Melanoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Melanoma+11 MoreCAB-AXL-ADC - Biological
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer drug to see if it is safe and effective.

Eligible Conditions
  • Melanoma
  • Bone Sarcoma
  • Leiomyosarcoma
  • Liposarcoma
  • Osteosarcoma
  • Ewing Sarcoma
  • Synovial Sarcoma
  • Soft Tissue Sarcoma
  • Sarcoma
  • Refractory Sarcoma
  • Solid Tumors
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
ABSK021
1
Seclidemstat
1
Metronomic dosing

Study Objectives

7 Primary · 13 Secondary · Reporting Duration: Up to 24 months

Week 3
Dose Limiting Toxicities (DLTs)
Up to 24 months
Anti-tumor activity
Frequency and severity of Treatment-Emergent Adverse Events (Safety and Tolerability of BA3011)
Immunogenicity of BA3011
Pharmacokinetics: AUC
Pharmacokinetics: Cmax
Phase 1 and 2: Best overall response (OR)
Phase 1 and 2: Disease control rate (DCR)
Phase 1 and 2: Duration of response (DOR)
Phase 1 and 2: Overall survival (OS)
Phase 1 and 2: Progression-free survival (PFS)
Phase 1 and 2: Safety Profile
Phase 1 and 2: Time to response (TTR)
Phase 1 and 2: Tumor size
Phase 1: Immunogenicity
Phase 1: Overall response rate (ORR)
Phase 1: Pharmacokinetics
Phase 1: Safety Profile
Phase 2: Confirmed overall response rate (ORR) per RECIST v1.1
Week 3
Maximum Tolerated Dose (MTD)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
ABSK021
1
Seclidemstat
1
Metronomic dosing

Trial Design

2 Treatment Groups

BA3011
1 of 2
Combination Therapy
1 of 2

Experimental Treatment

120 Total Participants · 2 Treatment Groups

Primary Treatment: CAB-AXL-ADC · No Placebo Group · Phase 1 & 2

BA3011
Biological
Experimental Group · 1 Intervention: CAB-AXL-ADC · Intervention Types: Biological
Combination TherapyExperimental Group · 2 Interventions: CAB-AXL-ADC, PD-1 inhibitor · Intervention Types: Biological, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PD-1 inhibitor
2019
Completed Phase 2
~580

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 24 months

Who is running the clinical trial?

BioAtla, Inc.Lead Sponsor
5 Previous Clinical Trials
796 Total Patients Enrolled
2 Trials studying Melanoma
456 Patients Enrolled for Melanoma

Eligibility Criteria

Age Any Age · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top